High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study

Abergel, Armand; Hézode, C.; Asselah, Tarik; Larrey, Dominique; Gournay, Jérôme; Loustaud‐Ratti, Véronique; Martino, V. Di; Hubert, I.; Samuel, Didier; Chanteranne, Brigitte; Dodel, Marie; Faure, Frédéric; Pereira, B.; Lamblin, Geneviève; Campos, Cely Selma de Sousa; Muti, Leon; Reymond, Maud; Teilhet, Camille

doi:10.1016/s0168-8278(18)30437-9

Cited by 13 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two patients relapsed post-treatment (updated data provided to the panel by Merck). 88 Genotype 1b, Genotype-specific: Ritonavir-boosted paritaprevir, ombitasvir and dasabuvir Treatment-naïve and treatment-experienced patients infected with genotype 1b, without cirrhosis or with compensated (Child-Pugh A) cirrhosis, should be treated with the combination of ombitasvir, paritaprevir and ritonavir plus dasabuvir for 12 weeks (A1).…”

Section: Genotype 1b Genotype-specific: Grazoprevir/elbasvirmentioning

confidence: 99%

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Buonomo¹,

Scotto²,

Coppola³

et al. 2020

Medicine

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, and because of developments in diagnostic procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in Anti-HCV antibodies are detectable in serum or plasma by enzyme immunoassay (EIA) in the vast majority of patients with HCV infection, but EIA results may be negative in early acute Journal of Hepatology 2018 vol. 69 j 461-511 q Clinical practice guidelines panel: Chair: Jean-Michel Pawlotsky; EASL governing board representative: Francesco Negro; Panel members:

show abstract

Section: Genotype 1b Genotype-specific: Grazoprevir/elbasvirmentioning

confidence: 99%

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Buonomo¹,

Scotto²,

Coppola³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…Kürzlich wurden zwei Studien mit einer Therapieverkürzung auf 8 Wochen bei therapienaiven Patienten mit einer HCV-Genotyp-1b-Infektion und maximal einer F2-Fibrose auf der Grundlage einer transienten Elastografie der Leber (< 9,5 kPa) vorgestellt [60][61][62][63]. In der unkontrollierten einarmigen französischen Studie betrug die SVR-Rate 97 % (IIb) [60,61]. In der kontrollierten, randomisierten Studie aus Taiwan betrugen die SVR-Raten 88 % im 8-und 100 % im 12-Wochen-Arm (Ib) [63].…”

Section: Hcv-genotypunclassified

Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion

et al. 2020

View full text Add to dashboard Cite

“…According to SmPC and guidelines prolongation of treatment to 16 weeks was recommended in the case of presence of a specific NS5A polymorphism and baseline viral load over 800 000 IU/ml in patients infected with GT1a and GT4 [36]. On the other hand, high efficacy (97%) of the shortened GZR/EBR regimen in GT1b infected patients with non-advanced liver fibrosis demonstrated recently in the phase-3 Streager study supports possible 8-week therapy in such a population [37].…”

Section: Genotype Specific Direct Acting Antiviralsmentioning

confidence: 99%

Viral hepatitis C treatment shortening – what is the limit?

Zarębska-Michaluk

2019

ceh

View full text Add to dashboard Cite

Successful antiviral treatment for hepatitis C virus (HCV) infection is crucial to prevent progression of the disease and its most serious complications. Therapy options have changed over the years with improvement of treatment efficacy, safety and simplification. They evolved from interferon and ribavirin combination administered for 24-72 weeks through interferon (IFN)-based triple therapies with 24-48 weeks duration to the all-oral, well-tolerated direct-acting antiviral regimens lasting for 8-16 weeks and with almost 100% cure rates. The benefits of shorter treatment duration are cost reduction, access to therapy for more patients, and lower risk of adverse events and nonadherence. This review summarizes data on treatment options, focusing on the recommended durations of different regimens depending on HCV genotype, severity of liver disease and history of previous therapy. According to currently available data, shortening treatment below 8 weeks does not provide additional benefits, although the further simplification of therapy is still a subject of study.

show abstract

High efficacy and safety of grazoprevir and elbasvir for 8 weeks in treatment-naive, non-severe fibrosis HCV GT1b-infected patients: Interim Results of the STREAGER Study

Cited by 13 publications

References 0 publications

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence

Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion

Viral hepatitis C treatment shortening – what is the limit?

Contact Info

Product

Resources

About